Elevated RIPK3 correlates with disease burden in myelofibrosis

Blood Adv. 2023 Apr 11;7(7):1219-1224. doi: 10.1182/bloodadvances.2021006838.

Veronika Dill^{1

2

3}, Celina V Wagner¹, Eva C Keller^{1

4}, Francisco Jose Fernandez-Hernandez⁵, Khalid Shoumariyeh^{6

7}, Timo O Odinius¹, Lars Buschhorn⁸, Richard T Hauch⁹, Christian Suren¹⁰, Judith S Hecker^{1

2

3}, Peter Herhaus¹, Michael Sandherr¹¹, Burkhard Schmidt¹², Julia Slotta-Huspenina⁴, Florian Bassermann^{1

3

13}, Ulrike Höckendorf¹, Stefanie Jilg¹⁴, Caterina Branca¹, Sebastian Vosberg⁵, Philipp J Jost^{1

5}

¹ Department of Internal Medicine III, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
² German Cancer Consortium, Partner Site Munich, Munich, Germany.
³ German Cancer Research Center, Heidelberg, Germany.
⁴ Institute of Pathology, Technical University of Munich, Munich, Germany.
⁵ Clinical Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
⁶ Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁷ German Cancer Consortium, Partner Site Freiburg, Freiburg, Germany.
⁸ National Center for Tumor Diseases, Heidelberg, Germany.
⁹ Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
¹⁰ Department of Orthopedics and Sports Orthopedics, School of Medicine, University hospital rechts der Isar, Technical University of Munich, Munich, Germany.
¹¹ Gemeinschaftspraxis Hämato-Onkologie Weilheim, Weilheim, Germany.
¹² Gemeinschaftspraxis Hämato-Onkologie Pasing, Munich, Germany.
¹³ Center for Translational Cancer Research (TranslaTUM), Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
¹⁴ Gemeinschaftspraxis Onkologie Erding, Erding, Germany.

No abstract available

Publication types